??
交易撮合者擔心，債市動蕩和全球不穩定可能會影響2016年的并購活動，今年的并購交易達到空前高位，超過2007年的峰值水平。
根據湯森路透(Thomson Reuters)的數據，受到制藥、能源和消費行業并購急劇增加的推動，已宣布并購交易總額升至4.6萬億美元，高于8年前的4.3萬億美元。
其中很多交易規模達到數百億甚至數千億美元，這些大規模并購包括制藥商輝瑞(Pfizer)和艾爾建(Allergan)、釀酒企業百威英博(AB InBev)和南非米勒啤酒(SABMiller)以及石油巨擘荷蘭皇家殼牌(Royal Dutch Shell)和英國天然氣集團(BG Group)。
在疲弱經濟環境下對增長的渴望、廉價融資以及維權股東繼續施壓提高回報，推動很多公司合并。
交易撮合者表示，2016年，這些基本面因素仍會大體存在。然而，很多企業也警告稱，業內同行日益擔心：一場像上月巴黎那樣的新的恐怖襲擊或者又一場金融危機可能損害企業信心，終結本輪并購行情。（中國進出口網）
Dealmakers are worried that bond market turmoil and global instability could hit mergers and acquisitions in 2016 after deals reached an all-time high this year, surpassing 2007’s peak.
Driven by a surge of tie-ups in the pharmaceuticals, energy and consumer sectors, the total value of announced transactions has climbed to $4.6tn, compared with $4.3tn eight years ago, according to Thomson Reuters data.
Many of these deals have been for tens or hundreds of billions of dollars, including blockbuster tie-ups between drugmakers Pfizer and Allergan, brewers AB InBev and SABMiller, and oil majors Royal Dutch Shell and BG Group.
Hunger for growth in a weak economic environment, cheap financing and continued pressure from activist shareholders to boost returns drove many companies to combine.
Dealmakers have said these fundamentals remain broadly intact for 2016. However, many have also warned of growing fears among their peers that a fresh terror attack, like that in Paris last month, or another financial crisis could tarnish business confidence and bring the M&A run to an end.
